Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism

Ichiro Ieiri, Y. Kishimoto, H. Okochi, K. Momiyama, T. Morita, M. Kitano, T. Morisawa, Y. Fukushima, K. Nakagawa, J. Hasegawa, K. Otsubo, T. Ishizaki

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Background: Little is known about differences in the disposition kinetics and pharmacological effects on gastrin levels between lansoprazole and rabeprazole given in a repeated dosing scheme with respect to the polymorphic CYP2C19. Aim: To provide preliminary information that should be considered when prescribing proton-pump inhibitors (PPIs) for the treatment of acid-related diseases with reference to the CYP2C19 genotypic status. Methods: Helicobacter pylori-negative healthy volunteers were divided into the following three groups (n=5 each) on the basis of genotyping for CYP2C19: homozygous (hmEMs) and heterozygous extensive metabolizers (htEMs), and poor metabolizers (PMs). All received once-daily 30-mg doses of lansoprazole or 10-mg doses of rabeprazole during an 8-day course in a crossover manner. Results: The relative values for the area under the serum concentration-time curve (AUC) of lansoprazole and rabeprazole in the hmEMs, htEMs, and PMs after the final doses were 1:1.7:3.9 and 1:1.7:3.8, respectively. The relative AUCs of gastrin in the hmEMs, htEMs, and PMs were 1.6:2.6:3.1 for lansoprazole and 1.6:2.6:2.9 for rabeprazole, respectively. Conclusion: The disposition kinetic behavior of the two PPIs is co-segregated with CYP2C19. The magnitude of CYP2C19-dependent drug availability in the systemic circulation and resulting gastrin response appears to be fairly similar between the two drugs within the same CYP2C19 genotypic groups after a multiple-dosing regimen.

Original languageEnglish
Pages (from-to)485-492
Number of pages8
JournalEuropean Journal of Clinical Pharmacology
Volume57
Issue number5-6
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

Rabeprazole
Lansoprazole
Gastrins
Serum
Proton Pump Inhibitors
Area Under Curve
Helicobacter pylori
Pharmaceutical Preparations
Cytochrome P-450 CYP2C19
Healthy Volunteers
Pharmacology
Acids

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism. / Ieiri, Ichiro; Kishimoto, Y.; Okochi, H.; Momiyama, K.; Morita, T.; Kitano, M.; Morisawa, T.; Fukushima, Y.; Nakagawa, K.; Hasegawa, J.; Otsubo, K.; Ishizaki, T.

In: European Journal of Clinical Pharmacology, Vol. 57, No. 5-6, 2001, p. 485-492.

Research output: Contribution to journalArticle

Ieiri, I, Kishimoto, Y, Okochi, H, Momiyama, K, Morita, T, Kitano, M, Morisawa, T, Fukushima, Y, Nakagawa, K, Hasegawa, J, Otsubo, K & Ishizaki, T 2001, 'Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism', European Journal of Clinical Pharmacology, vol. 57, no. 5-6, pp. 485-492.
Ieiri, Ichiro ; Kishimoto, Y. ; Okochi, H. ; Momiyama, K. ; Morita, T. ; Kitano, M. ; Morisawa, T. ; Fukushima, Y. ; Nakagawa, K. ; Hasegawa, J. ; Otsubo, K. ; Ishizaki, T. / Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism. In: European Journal of Clinical Pharmacology. 2001 ; Vol. 57, No. 5-6. pp. 485-492.
@article{3e002d6b607c48c99857c76c4b0dc5d6,
title = "Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism",
abstract = "Background: Little is known about differences in the disposition kinetics and pharmacological effects on gastrin levels between lansoprazole and rabeprazole given in a repeated dosing scheme with respect to the polymorphic CYP2C19. Aim: To provide preliminary information that should be considered when prescribing proton-pump inhibitors (PPIs) for the treatment of acid-related diseases with reference to the CYP2C19 genotypic status. Methods: Helicobacter pylori-negative healthy volunteers were divided into the following three groups (n=5 each) on the basis of genotyping for CYP2C19: homozygous (hmEMs) and heterozygous extensive metabolizers (htEMs), and poor metabolizers (PMs). All received once-daily 30-mg doses of lansoprazole or 10-mg doses of rabeprazole during an 8-day course in a crossover manner. Results: The relative values for the area under the serum concentration-time curve (AUC) of lansoprazole and rabeprazole in the hmEMs, htEMs, and PMs after the final doses were 1:1.7:3.9 and 1:1.7:3.8, respectively. The relative AUCs of gastrin in the hmEMs, htEMs, and PMs were 1.6:2.6:3.1 for lansoprazole and 1.6:2.6:2.9 for rabeprazole, respectively. Conclusion: The disposition kinetic behavior of the two PPIs is co-segregated with CYP2C19. The magnitude of CYP2C19-dependent drug availability in the systemic circulation and resulting gastrin response appears to be fairly similar between the two drugs within the same CYP2C19 genotypic groups after a multiple-dosing regimen.",
author = "Ichiro Ieiri and Y. Kishimoto and H. Okochi and K. Momiyama and T. Morita and M. Kitano and T. Morisawa and Y. Fukushima and K. Nakagawa and J. Hasegawa and K. Otsubo and T. Ishizaki",
year = "2001",
language = "English",
volume = "57",
pages = "485--492",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",
number = "5-6",

}

TY - JOUR

T1 - Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism

AU - Ieiri, Ichiro

AU - Kishimoto, Y.

AU - Okochi, H.

AU - Momiyama, K.

AU - Morita, T.

AU - Kitano, M.

AU - Morisawa, T.

AU - Fukushima, Y.

AU - Nakagawa, K.

AU - Hasegawa, J.

AU - Otsubo, K.

AU - Ishizaki, T.

PY - 2001

Y1 - 2001

N2 - Background: Little is known about differences in the disposition kinetics and pharmacological effects on gastrin levels between lansoprazole and rabeprazole given in a repeated dosing scheme with respect to the polymorphic CYP2C19. Aim: To provide preliminary information that should be considered when prescribing proton-pump inhibitors (PPIs) for the treatment of acid-related diseases with reference to the CYP2C19 genotypic status. Methods: Helicobacter pylori-negative healthy volunteers were divided into the following three groups (n=5 each) on the basis of genotyping for CYP2C19: homozygous (hmEMs) and heterozygous extensive metabolizers (htEMs), and poor metabolizers (PMs). All received once-daily 30-mg doses of lansoprazole or 10-mg doses of rabeprazole during an 8-day course in a crossover manner. Results: The relative values for the area under the serum concentration-time curve (AUC) of lansoprazole and rabeprazole in the hmEMs, htEMs, and PMs after the final doses were 1:1.7:3.9 and 1:1.7:3.8, respectively. The relative AUCs of gastrin in the hmEMs, htEMs, and PMs were 1.6:2.6:3.1 for lansoprazole and 1.6:2.6:2.9 for rabeprazole, respectively. Conclusion: The disposition kinetic behavior of the two PPIs is co-segregated with CYP2C19. The magnitude of CYP2C19-dependent drug availability in the systemic circulation and resulting gastrin response appears to be fairly similar between the two drugs within the same CYP2C19 genotypic groups after a multiple-dosing regimen.

AB - Background: Little is known about differences in the disposition kinetics and pharmacological effects on gastrin levels between lansoprazole and rabeprazole given in a repeated dosing scheme with respect to the polymorphic CYP2C19. Aim: To provide preliminary information that should be considered when prescribing proton-pump inhibitors (PPIs) for the treatment of acid-related diseases with reference to the CYP2C19 genotypic status. Methods: Helicobacter pylori-negative healthy volunteers were divided into the following three groups (n=5 each) on the basis of genotyping for CYP2C19: homozygous (hmEMs) and heterozygous extensive metabolizers (htEMs), and poor metabolizers (PMs). All received once-daily 30-mg doses of lansoprazole or 10-mg doses of rabeprazole during an 8-day course in a crossover manner. Results: The relative values for the area under the serum concentration-time curve (AUC) of lansoprazole and rabeprazole in the hmEMs, htEMs, and PMs after the final doses were 1:1.7:3.9 and 1:1.7:3.8, respectively. The relative AUCs of gastrin in the hmEMs, htEMs, and PMs were 1.6:2.6:3.1 for lansoprazole and 1.6:2.6:2.9 for rabeprazole, respectively. Conclusion: The disposition kinetic behavior of the two PPIs is co-segregated with CYP2C19. The magnitude of CYP2C19-dependent drug availability in the systemic circulation and resulting gastrin response appears to be fairly similar between the two drugs within the same CYP2C19 genotypic groups after a multiple-dosing regimen.

UR - http://www.scopus.com/inward/record.url?scp=0034805578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034805578&partnerID=8YFLogxK

M3 - Article

C2 - 11699613

VL - 57

SP - 485

EP - 492

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 5-6

ER -